Learn More
Invitrogen™ RET Monoclonal Antibody (8D10C9)

Description
MA5-15364 targets RET in indirect ELISA, WB applications and shows reactivity with Human samples. The MA5-15364 immunogen is purified recombinant fragment of RET (aa896-1063) expressed in E. Coli.
Specifications
Specifications
| Antigen | RET |
| Applications | ELISA, Western Blot |
| Classification | Monoclonal |
| Clone | 8D10C9 |
| Concentration | Conc. Not Determined |
| Conjugate | Unconjugated |
| Formulation | ascites with 0.03% sodium azide |
| Gene | RET |
| Gene Accession No. | P07949 |
| Gene Alias | Cadherin family member 12; Cadherin family member 12 (CDHF12); Cadherin related family member 16 (CDHR16); cadherin-related family member 16; CDHF12; CDHR16; CG1061; CG14396; CG14396-PA; CG14396-PB; CG14396-PC; c-Ret; CUX1/RET fusion; Dmel\CG14396; Dmel_CG14396; DmHD-59; DmRet; Dret; D-ret; EC 2.7.10.1; ELKS; Extracellular cell-membrane anchored RET cadherin 120 kDa fragment; HD-59; HSCR1; Hydroxyaryl protein kinase; hydroxyaryl-protein kinase; kinase Ret; MEN2; MEN2A; MEN2B; MTC1; Multiple endocrine neoplasia and medullary thyroid carcinoma 1; Oncogene RET; OTTHUMP00000216967; proto-oncogene c-Ret; Proto-oncogene tyrosine-protein kinase receptor Ret; PTC; rearranged during transfection; receptor tyrosine kinase; ret; RET ELE1; Ret gene for receptor tyrosin; Ret oncogene; ret proto-oncogene; ret proto-oncogene (multiple endocrine neoplasia and medullary thyroid carcinoma 1, Hirschsprung disease); Ret proto-oncogene (multiple endocrine neoplasia MEN2A MEN2B and medullary thyroid carcinoma 1 Hirschsprung disease); RET receptor tyrosine kinase; RET transforming sequence; RET51; RET9; RET-ELE1; Reto; Ret-PA; Ret-PB; Ret-PC; Soluble RET kinase fragment |
| Show More |
Safety and Handling
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.